Kiniksa (KNSA) officer sold 3,523 shares under 10b5-1 plan

Rhea-AI Filing Summary

Kiniksa Pharmaceuticals (KNSA) insider sale: Ross Moat, Chief Corporate & Commercial Officer and director, reported a disposition of 3,523 Class A ordinary shares on 09/04/2025 at a price of $35.31 per share. Following the sale, Mr. Moat beneficially owned 9,415 Class A ordinary shares directly. The filing notes the sale was executed pursuant to a 10b5-1 trading plan adopted on November 13, 2024. The Form 4 was signed by an attorney-in-fact on 09/08/2025.

Insights

Securities Analyst

TL;DR: Routine insider sale under a pre-established 10b5-1 plan; transaction size appears modest relative to company scale.

The sale of 3,523 shares at $35.31 was reported as a planned disposition under a 10b5-1 plan dated 11/13/2024, indicating the transaction was pre-authorized and likely not based on undisclosed material information. The remaining direct holding is 9,415 shares. For investors, a single planned sale by an officer typically carries limited informational value absent larger related changes in holdings or concurrent material disclosures.

Corporate Governance Expert

TL;DR: Compliance-focused disclosure; use of 10b5-1 plan reduces insider trading concerns.

The Form 4 shows appropriate disclosure of an officer/director sale executed via a documented 10b5-1 plan, which supports compliance with Section 16 reporting obligations. The filing includes required details: transaction date, price, shares sold, and post-transaction ownership. No amendments or additional transactions are reported. This filing appears procedural rather than indicative of governance issues.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Moat Ross

(Last) (First) (Middle)

23 OLD BOND STREET, THIRD FLOOR

(Street)

LONDON X0 W1S 4PZ

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Kiniksa Pharmaceuticals International, plc [ KNSA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF CORP. & COMM. OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
09/04/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Ordinary Share	09/04/2025		S(1)		3,523	D	$35.31	9,415	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on November 13, 2024.

	/s/ Aaron Young, Attorney-in-Fact	09/08/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did KNSA report for Ross Moat?

Ross Moat reported a sale of 3,523 Class A ordinary shares on 09/04/2025 at $35.31 per share.

Was the KNSA transaction part of a 10b5-1 trading plan?

Yes. The Form 4 states the transaction was effected pursuant to a 10b5-1 plan executed on November 13, 2024.

How many KNSA shares does Ross Moat own after the reported sale?

Following the transaction, Mr. Moat beneficially owned 9,415 Class A ordinary shares directly.

What is Ross Moat’s role at Kiniksa (KNSA)?

The filing lists Ross Moat as a Director and the company’s Chief Corporate & Commercial Officer.